For instance, therapies that could achieve ghrelin cell–selective IR blockade would presumably help protect against insulin-induced hypoglycemia (by preventing insulin-induced drops in ghrelin) without gains in body weight, which are often considered unwelcome. The gene discussed is INS; the disease is Hypoglycemia.